Vanguard Fiduciary Trust
ARQT icon

Vanguard Fiduciary Trust’s Arcutis Biotherapeutics ARQT Stock Holding History

Vanguard Fiduciary Trust’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21.4M Buy
815,138
+43,374
+6% +$1.01M ﹤0.01% 1383
2026
Q1 		$18.2M Buy
+771,764
New +$19.7M ﹤0.01% 1389

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Fiduciary Trust's ARQT Position: Q2 2026 in Review

Vanguard Fiduciary Trust increased its Arcutis Biotherapeutics (ARQT) stake by 5.6% in Q2 2026, buying an estimated $1.01M and bringing the position to 815,138 shares worth $21.4M. The position accounts for ﹤0.01% of the portfolio, ranked #1383.

Vanguard Fiduciary Trust first reported a position in ARQT in Q1 2026 and has held it in 2 quarters since. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Vanguard Fiduciary Trust held 815,138 shares of Arcutis Biotherapeutics worth $21.4M as of Q2 2026.
  • Vanguard Fiduciary Trust bought 43,374 Arcutis Biotherapeutics shares in Q2 2026, an estimated $1.01M.
  • Arcutis Biotherapeutics made up ﹤0.01% of Vanguard Fiduciary Trust's portfolio in Q2 2026, its #1383 holding.
  • Vanguard Fiduciary Trust first reported a position in Arcutis Biotherapeutics in Q1 2026 and has held it in 2 quarters since.
  • 272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Vanguard Fiduciary Trust's 13F filing for Q2 2026, filed 13 Aug 2026.